Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Molecular Cancer Therapeutics|July 18, 2013
Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancerYezi Zhu, Chengfei Liu, Nagalakshmi Nadiminty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2014
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancerChengfei Liu, Wei Lou, Yezi Zhu, et al.
The Prostate|June 18, 2011
RhoGDIα suppresses growth and survival of prostate cancer cellsYezi Zhu, Ramakumar Tummala, Chengfei Liu, et al.
Cancer Research|February 5, 2015
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate CancerChengfei Liu, Wei Lou, Yezi Zhu, et al.
The American Journal of Pathology|June 25, 2013
Lin28 promotes growth of prostate cancer cells and activates the androgen receptorRamakumar Tummala, Nagalakshmi Nadiminty, Wei Lou, et al.
The Prostate|May 4, 2011
Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasionMeng Sun, Chengfei Liu, Nagalakshmi Nadiminty, et al.
The Prostate|September 22, 2012
Functional p53 determines docetaxel sensitivity in prostate cancer cellsChengfei Liu, Yezi Zhu, Wei Lou, et al.
Genes & Cancer|July 23, 2011
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancerChengfei Liu, Nagalakshmi Nadiminty, Ramakumar Tummala, et al.
The Journal of Biological Chemistry|December 1, 2011
MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cellsNagalakshmi Nadiminty, Ramakumar Tummala, Wei Lou, et al.
Nature Communications|June 3, 2020
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancerKeliang Wang, Jie Luo, Shuyuan Yeh, et al.
Pageof 3